Subscribe to RSS
DOI: 10.1055/a-1976-9694
Speicheldrüsenkarzinome – Monozentrische Erfahrung zu Subtypen und deren Inzidenz über 42 Jahre
Salivary gland carcinomas – Monocentric experience on subtypes and their incidences over 42 years
Zusammenfassung
Hintergrund Speicheldrüsenkarzinome sind selten und heterogen. Über 20 Subtypen sind anerkannt und Risikofaktoren sind vielfältig. Ziel dieser Arbeit war die Bewertung des Subtyps und weiterer Risikofaktoren bei einem monozentrischen Kollektiv aus über vier Jahrzehnten.
Material und Methoden 205 Fälle (Diagnosezeitraum 1972–2014) wurden retrospektiv erhoben und hinsichtlich der Verteilung von Risikofaktoren und deren Einfluss auf die Gesamtüberlebenszeit (overall survival, OS) statistisch ausgewertet.
Ergebnisse 19/24 (79,2%) der in der WHO-Klassifikation gelisteten Subtypen kamen in der Kohorte selten vor (< 5%). Davon wurden 10/24 (41,7%) Subtypen nie diagnostiziert. Das Plattenepithelkarzinom (PEC), Adenokarzinom (AdenoCa), Azinuszellkarzinom (AzinusCa), Mukoepidermoidkarzinom (MEC) und adenoidzystische Karzinom (ACC) sind mit zusammen 145/205 (70,7%) die mit Abstand häufigsten Subtypen. Risikofaktoren sind in diesen Gruppen signifikant unterschiedlich vertreten (z.B. lymphogene Metastasierung und Differenzierungsgrad beim AdenoCa und Alter, T- und UICC-Stadium beim PEC). Das 5-Jahres-Gesamtüberleben aller Patienten war 66,9% und unterscheidet sich signifikant innerhalb der häufigsten Subtypen. Ein unabhängiger Einfluss auf das Gesamtüberleben war in der multivariaten Analyse feststellbar für das Alter der Patienten (p<0,001) sowie das T- (p=0,003) und N-Stadium (p=0,046).
Schlussfolgerungen Die meisten Subtypen traten auch innerhalb von Jahrzehnten ausgesprochen selten oder gar nicht auf. Die häufigsten Diagnosen unterscheiden sich bezüglich der Risikofaktoren als auch hinsichtlich des OS, sodass 3 Risikogruppen gebildet werden können. Schlussfolgernd ist die Betrachtung von TNM alleine für die Prognoseabschätzung beim Speicheldrüsenkarzinom unzureichend.
Abstract
Objective Salivary gland carcinomas are rare and heterogeneous. More than 20 subtypes are recognized and risk factors are diverse. The aim of this work was to evaluate the subtype and other risk factors in a monocentric population from more than four decades.
Material and Methods 205 cases (diagnosis period 1972–2014) were retrospectively collected and analyzed with regard to the distribution of risk factors and their influence on overall survival (OS).
Results 19/24 (79.2%) of the subtypes listed in the WHO classification occurred rarely in the cohort (< 5%). 10/24 (41.7%) of all subtypes were never diagnosed. With a total of 145/205 cases (70.7%), squamous cell carcinoma (PEC), adenocarcinoma (AdenoCa), acinar cell carcinoma (AcinarCa), mucoepidermoid carcinoma (MEC), and adenoid cystic carcinoma (ACC) were by far the most common subtypes. Risk factors are significantly different in these groups (e.g., lymphogenic metastasis and degree of differentiation in AdenoCa and age, T and UICC stage in PEC). The 5-year overall survival of all patients was 66.9% and differed significantly within the most common subtypes. An independent impact on overall survival was detectable for patient age (p<0.001), and T- (p=0.003) and N-stage (p=0.046) in multivariate analysis.
Conclusions Most subtypes occurred markedly rarely or not at all within decades. The most common diagnoses differ with respect to risk factors as well as OS and 3 risk groups can be defined based on histology. In conclusion, considering TNM alone is insufficient for prognosis estimation in salivary gland carcinoma.
Schlüsselwörter
Speicheldrüsenkarzinome - histologische Subtypen - Inzidenz - monozentrischer Erfahrungsbericht - Gesamtüberleben - RisikofaktorenKeywords
salivary gland carcinomas - histologic subtypes - incidence - monocentric experience report - overall survival - risk factors* Geteilte Erstautorenschaft.
‡ Geteilte Letztautorenschaft.
Publication History
Received: 13 April 2022
Accepted: 09 November 2022
Article published online:
21 December 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Barnes L, Eveson JW, Sidransky D. et al. Pathology and genetics of head and neck tumours: IARC;. 2005
- 2 Ihrler S, Guntinas-Lichius O, Haas C. et al. Updates on tumours of the salivary glands : 2017 WHO classification. Pathologe 2018; 39: 11-17 DOI: 10.1007/s00292-017-0407-5. (PMID: 29372306)
- 3 Terhaard CH, Lubsen H, Van der Tweel I. et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck discussion 692–683 2004; 26: 681-692 DOI: 10.1002/hed.10400.
- 4 Bjorndal K, Krogdahl A, Therkildsen MH. et al. Salivary gland carcinoma in Denmark 1990–2005: outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 2012; 48: 179-185 DOI: 10.1016/j.oraloncology.2011.09.005. (PMID: 21968090)
- 5 Ata-Ali J, Zurriaga O, Alberich C. Incidence and survival rates for malignant salivary gland tumors. J Oral Sci 2016; 58: 67-73 DOI: 10.2334/josnusd.58.67. (PMID: 27021542)
- 6 Pan SY, de Groh M, Morrison H. A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. J Cancer Epidemiol 2017; 2017: 4909214 DOI: 10.1155/2017/4909214. (PMID: 28133481)
- 7 Carlson J, Licitra L, Locati L. et al. Salivary gland cancer: an update on present and emerging therapies. Am Soc Clin Oncol Educ Book 2013; 257-263 DOI: 10.1200/EdBook_AM.2013.33.257.
- 8 Beal KP, Singh B, Kraus D. et al. Radiation-induced salivary gland tumors: a report of 18 cases and a review of the literature. Cancer J 2003; 9: 467-471 DOI: 10.1097/00130404-200311000-00006. (PMID: 14740975)
- 9 Vander Poorten VL, Balm AJ, Hilgers FJ. et al. The development of a prognostic score for patients with parotid carcinoma. Cancer 1999; 85: 2057-2067
- 10 Bhattacharyya N, Fried MP. Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 2005; 26: 39-44 DOI: 10.1016/j.amjoto.2004.06.017. (PMID: 15635580)
- 11 Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8: 177-184 DOI: 10.1002/hed.2890080309. (PMID: 3744850)
- 12 Thackray A. Histological typing of salivary gland tumors. International Histological Classification of Tumors No 7 1972.
- 13 Seifert G, Brocheriou C, Cardesa A. et al. WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours. Pathol Res Pract 1990; 186: 555-581 DOI: 10.1016/S0344-0338(11)80220-7. (PMID: 1962854)
- 14 Reinheimer A, Vieira DS, Cordeiro MM. et al. Retrospective study of 124 cases of salivary gland tumors and literature review. J Clin Exp Dent 2019; 11: e1025-e1032 DOI: 10.4317/jced.55685. (PMID: 31700577)
- 15 de Oliveira FA, Duarte EC, Taveira CT. et al. Salivary gland tumor: a review of 599 cases in a Brazilian population. Head Neck Pathol 2009; 3: 271-275 DOI: 10.1007/s12105-009-0139-9. (PMID: 20596844)
- 16 Cunha JL, Coimbra AC, Silva JV. et al. Epidemiologic analysis of salivary gland tumors over a 10-years period diagnosed in a northeast Brazilian population. Med Oral Patol Oral Cir Bucal 2020; 25: e516-e522 DOI: 10.4317/medoral.23532. (PMID: 32388524)
- 17 Boukheris H, Curtis RE, Land CE. et al. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18: 2899-2906 DOI: 10.1158/1055-9965.EPI-09-0638. (PMID: 19861510)
- 18 Vasconcelos AC, Nor F, Meurer L. et al. Clinicopathological analysis of salivary gland tumors over a 15-year period. Braz Oral Res 2016; 30 DOI: 10.1590/1807-3107BOR-2016.vol30.0002. (PMID: 26676198)